MedPage Today

FDA Approves Pivekimab Sunirine for Rare Blood Cancer BPDCN

(MedPage Today) -- The FDA approved the antibody-drug conjugate pivekimab sunirine (Decnupaz) for the rare hematologic malignancy blastic plasmacytoid dendritic cell neoplasm (BPDCN). The approval stipulates use of the drug in adults. Although...